

# ANTI-PSORIASIS EFFICACY TESTING FOR INJECTABLE DRUGS

Genoskin's InflammaSkin® platform features a T-cell driven skin inflammation model with a Th17/Th1 phenotype. It allows research on the efficacy of a drug candidate upon subcutaneous injection. Other models that mimic inflammatory features of psoriasis often lack tissue complexity and diversity of immune cells.

## Injectable InflammaSkin® services

Our data generation platform is based on an ex vivo bio-stabilized human skin model that features resident T-cell activation and a Th17/Th1 phenotype. The 3 layers of skin are preserved to allow subcutaneous and intradermal injection. The platform offers a 7 days experimental window to evaluate efficacy of anti-inflammatory and anti-psoriasis drugs.



## How we generate data to evaluate the efficacy of your anti-psoriasis molecule

### Skin inflammation

Th17/Th1 activation through multiplex analysis of cytokine release  
(see figures below)


### Tissue integrity & epidermal activation

histological analysis of psoriasis specific markers

### Spatial biology

MANTIS®, a multiplex imaging solution dedicated to immune cells profiling in skin

Pharmacological response to InflammaSkin® treated with adalimumab subcutaneously injected at D1



### Case Study

Evaluation of pharmacological responses to subcutaneous injection of adalimumab in InflammaSkin®, a full thickness ex vivo skin model reproducing key features of psoriatic lesions. C. Jarret (Genoskin), E. Bartnik (Sanofi-Aventis Deutschland), D. Ding-Pfennigdorff (Sanofi-Aventis Deutschland), E. Braun (Genoskin), P. Descargues (Genoskin) - ESDR 2019



[www.genoskin.com](http://www.genoskin.com)